Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT01761656

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01761656
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01761656. Randomized; no masking; primary purpose prevention. Start 2012-12 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR
Acronym
ARMYDA-IMR
Condition
Stable Angina
Condition
Unstable Angina
Condition
Acute Non-ST-segment Elevation Myocardial Infarction
Intervention (Drug)
loading dose atorvastatin
Intervention (Drug)
conventional dose atorvastatin
Lead sponsor
Central South University (class: other)

Record details

Record id
cardio:ct-nct01761656
Content hash
5998cf26f59c185a4b1c64e4c92cba7d25edfd653dc02efde07baaf2bf6b52fd